{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T10:41:47Z","timestamp":1773052907277,"version":"3.50.1"},"reference-count":0,"publisher":"Science Repository OU","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CDM"],"published-print":{"date-parts":[[2019,12,31]]},"abstract":"<jats:p>Background: Stress cardiac magnetic resonance (CMR) imaging with myocardial perfusion reserve index\n(MPRI) measurement has emerged as a noninvasive method for assessing coronary microvascular\ndysfunction (CMD) in the absence of obstructive coronary artery disease (CAD). Pharmacologic stress with\nadenosine or regadenoson is typically used with comparable coronary vasodilation, but higher unadjusted\nMPRI has been reported with regadenoson in healthy men. This difference has not been assessed in\nsymptomatic or healthy women.\nMethods: In a prospective cohort study, 139 symptomatic women with suspected CMD and no obstructive\nCAD underwent stress CMR and invasive coronary flow reserve (CFR) testing. Adenosine was the default\nvasodilator (n=99), while regadenoson was used if history of asthma or prior adenosine intolerance (n=40).\nStress CMR was also performed in 40 age-matched healthy controls using adenosine (n=20) and\nregadenoson (n=20). Unpaired t-tests and analysis of covariance were performed to compare MPRI with\nadenosine and regadenoson in the symptomatic women and healthy controls.\nResults: Compared to regadenoson cases, adenosine cases had lower invasive CFR (2.64\u00b10.62 vs\n2.94\u00b10.68, p=0.01) and pharmacologic heart rate change (28\u00b116 vs 38\u00b115 bpm, p=0.0008). Unadjusted\nMPRI was lower in the adenosine compared to regadenoson cases (1.73\u00b10.38 vs 2.27\u00b10.59, p&lt;0.0001).\nWhen adjusted for heart rate, rate-pressure-product, and invasive CFR, MPRI remained lower in the\nadenosine cases (p&lt;0.0001). Invasive CFR to adenosine correlated with adenosine MPRI (r 0.17, p=0.02)\nbut not regadenoson MPRI (r -0.14, p=0.19). There was no significant difference in MPRI in the controls\nwho received adenosine vs regadenoson (2.27\u00b10.33 vs 2.38\u00b10.44, p=0.36).\nConclusion: In women undergoing stress CMR for suspected CMD, those who received adenosine had\nlower MPRI than those who received regadenoson. However, there were no differences in MPRI in the\nhealthy controls. These findings suggest there may be physiologic differences in adenosine and\nregadenoson response in the coronary microcirculation of symptomatic women.<\/jats:p>","DOI":"10.31487\/j.cdm.2019.01.01","type":"journal-article","created":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T20:14:29Z","timestamp":1578600869000},"page":"1-7","source":"Crossref","is-referenced-by-count":2,"title":["Adenosine vs Regadenoson Pharmacologic Stress Differs in Women with Suspected Coronary Microvascular Dysfunction: A Report from the Women\u2019s Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction (WISE-CVD) Study"],"prefix":"10.31487","author":[{"given":"C. Noel Bairey","family":"Merz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puja K.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Rogatko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Behzad","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Noel Bairey","family":"Merz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl J.","family":"Pepine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrisandra","family":"Shufelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel S.","family":"Berman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen","family":"Handberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galen","family":"Cook-Wiens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Sopko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise E.","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish","family":"Motwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sawan","family":"Jalnapurkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherwin","family":"Dela Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16472","published-online":{"date-parts":[[2019,12,31]]},"container-title":["Cardiovascular Disorder and Medicine"],"original-title":[],"deposited":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T20:14:29Z","timestamp":1578600869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciencerepository.org\/adenosine-vs-regadenoson-pharmacologic-stress-differs-in-women_CDM-2019-1-101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,31]]},"references-count":0,"URL":"https:\/\/doi.org\/10.31487\/j.cdm.2019.01.01","relation":{},"subject":[],"published":{"date-parts":[[2019,12,31]]}}}